このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Unity Biotechnology 過去の業績

過去基準チェック /06

Unity Biotechnologyは19.3%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで15.5%毎年増加している。売上は成長しており、年平均28.3%の割合である。

主要情報

19.3%

収益成長率

36.6%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	28.3%
株主資本利益率	-168.3%
ネット・マージン	n/a
前回の決算情報	31 Mar 2024

Recent updates

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Mar 05

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Dec 22

A Look Inside Unity Bio's Transition To An Ophthalmology Company

Nov 27

収支内訳

Unity Biotechnology の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:UBX 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	0	-40	18	0
31 Dec 23	0	-40	19	0
30 Sep 23	0	-31	19	0
30 Jun 23	0	-30	20	0
31 Mar 23	0	-31	19	0
31 Dec 22	0	-44	20	0
30 Sep 22	5	-56	21	0
30 Jun 22	5	-59	22	0
31 Mar 22	5	-64	23	-9
31 Dec 21	5	-61	23	0
30 Sep 21	0	-70	23	-54
30 Jun 21	0	-81	24	-35
31 Mar 21	0	-82	24	-11
31 Dec 20	0	-94	24	0
30 Sep 20	0	-92	24	125
30 Jun 20	0	-86	23	106
31 Mar 20	0	-91	22	90
31 Dec 19	0	-82	20	0
30 Sep 19	0	-86	19	0
30 Jun 19	0	-83	18	0
31 Mar 19	0	-79	17	0
31 Dec 18	0	-76	16	59
30 Sep 18	1	-67	14	0
30 Jun 18	1	-60	12	0
31 Mar 18	1	-52	11	0
31 Dec 17	1	-45	10	0

質の高い収益: UBXは現在利益が出ていません。

利益率の向上: UBXは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: UBXは利益を出していないが、過去 5 年間で年間19.3%の割合で損失を削減してきた。

成長の加速: UBXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: UBXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: UBXは現在利益が出ていないため、自己資本利益率 ( -168.3% ) はマイナスです。

Unity Biotechnology 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020

Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020

Recent updates

Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024

Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

Unity Biotechnology, Inc. announced delayed annual 10-K filing

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss

Insufficient new directors

Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

New major risk - Financial position

Price target decreased by 13% to US$6.80

UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

New major risk - Revenue and earnings growth

Price target increased by 12% to US$8.80

Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema (Dme)

Price target increased by 8.8% to US$7.83

Price target decreased to US$38.00

Unity Biotechnology, Inc. Announces Positive 24-Week Data from Phase 2 Behold Study of UBX1325 in Patients with Diabetic Macular Edema

Price target increased to US$75.17

Price target increased to US$90.00

UNITY Biotechnology falls 7% on reverse stock split

Price target increased to US$7.83

Unity Biotechnology, Inc. Completes Enrollment in Phase 2 Envision Study of UBX1325 in Wet Age-Related Macular Degeneration

Unity Biotechnology cuts stock sales agreement in half to $25M

Unity Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

Unity Biotechnology Announces Positive Data in Phase 2 Behold Study of Ubx1325 in Patients with Diabetic Macular Edema

Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

UNITY Biotechnology Announces Board Changes

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022

Price target increased to US$7.50

UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degenera

Unity Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

Kristina Burow Resigns as Member of the Board and All of the Committees of the Board from Unity Biotechnology, Inc

Price target increased to US$7.50

Unity Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

Unity Biotechnology, Inc. Announces the Design for Its Phase 2 Study of Ubx1325 in Wet Age-Related Macular Degeneration and Anticipated Milestones for 2022

Chief Medical Officer notifies of intention to sell stock

A Look At Unity's UBX1325 Phase 1 Results

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell 3000E Index

Price target increased to US$6.86

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020

Price target increased to US$6.20

Unity Biotechnology, Inc. Appoints Alexander Nguyen as General Counsel

Unity Biotechnology, Inc. Announces New Preclinical Research That Reveals A Novel Mechanism for Treating Age-Related Eye Diseases

New 90-day high: US$7.51

Unity Biotechnology, Inc. Appoints Przemyslaw (Mike) Sapieha as Chief Scientific Advisor

New 90-day high: US$6.47

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Unity Biotechnology Announces Executive Changes

A Look Inside Unity Bio's Transition To An Ophthalmology Company

New 90-day high: US$4.78

Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

New 90-day low - US$2.94

Price target lowered to US$5.67

Unity Biotechnology, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

New 90-day high - US$9.96

Price target raised to US$23.33

Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell Microcap Value Index

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06